Syros Pharmaceuticals, Inc. (SYRS) Deferred Tax Assets, Valuation Allowance USD 2014 - 2023

Historical data

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Syros Pharmaceuticals, Inc. quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from 2014 to 2023.
  • Syros Pharmaceuticals, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending December 31, 2023 was $169 M, a 31.7% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $169 M +$40.7 M +31.7% Dec 31, 2023 10-K 2024-03-27
Q4 2022 $128 M -$18.1 M -12.4% Dec 31, 2022 10-K 2024-03-27
Q4 2021 $146 M +$31.3 M +27.3% Dec 31, 2021 10-K 2023-03-02
Q4 2020 $115 M +$24.7 M +27.4% Dec 31, 2020 10-K 2022-03-15
Q4 2019 $90.2 M +$23.2 M +34.6% Dec 31, 2019 10-K 2021-03-04
Q4 2018 $67 M +$19.5 M +40.9% Dec 31, 2018 10-K 2020-03-05
Q4 2017 $47.6 M +$7.95 M +20.1% Dec 31, 2017 10-K 2019-03-07
Q4 2016 $39.6 M +$18.5 M +87.8% Dec 31, 2016 10-K 2018-03-12
Q4 2015 $21.1 M +$11.4 M +118% Dec 31, 2015 10-K 2017-03-20
Q4 2014 $9.69 M Dec 31, 2014 10-K 2017-03-20
* An asterisk sign (*) next to the value indicates that the value is likely invalid.